#Samsung Biologics 207940 | Stock channels

Samsung Biologics207940

₩1,201,000-1.48%Close Oct 12

This is the start of #Samsung Biologics

Talk about Samsung Biologics here. Pull up price, chart, news and filings just for you from the message box, or mention @InverseOneBot to get an answer everyone can see.

InverseOne BotBOTOnly visible to you

Welcome to the Samsung Biologics channel. Here's the latest data.

삼성바이오로직스 207940

Close as of Oct 12

₩1,201,000-1.48%

Low ₩1,179,00052-week rangeHigh ₩1,987,000

At a glance: 3% of the 52-week range, estimated net outflow for 5 sessions in a row, filing check: Check one.

Disappears when you reload.

삼성바이오로직스 207940

Close as of Oct 12

₩1,201,000-1.48%

Low ₩1,179,00052-week rangeHigh ₩1,987,000

5 sessions

-16.0%

20 sessions

-16.6%

60 sessions

-13.9%

Volume

1.4x average

Price

Mar 31 ~ Oct 12

₩1,201,000-20.15%

Low ₩1,201,000High ₩1,616,000

Money flow

as of Oct 12

Outflow index-₩1.1B

Net flow, Outflow

Market flow rank: Outflow #30 of 52
Sector flow rank: #10 of 13

Multi-day trend, Persistent outflow

Cumulative flow: -₩11.9B
outflow: 5d streak

Estimated from public price, change and volume. Not actual investor net buying.

as of Oct 12

Market cap

₩55.6T

Lending balance

Little change

680,405 sh

KRW 0.82T

1D +0.11%5D +0.56%

New 52,687 sh, Returned 51,925 sh

Shares borrowed through securities lending that have not yet been returned. Borrowed shares are often sold afterwards, so the balance is used as a reference for pending sell pressure.

As of 2026-10-12, FSC stock lending data

Filing check

Check one1 to check first, 5 improvementschecked through Oct 14

This only counts facts confirmed in filings. It does not look at whether the price is cheap or expensive, and it is not a reason to buy or sell on its own.

Earnings quality

We read the latest periodic report and check whether profit matches cash, sales match receivables, and profit from the core business matches profit from elsewhere. There is no score, only the numbers that diverge beyond a threshold and why they matter.

2026 first half, consolidated statements, filed 2026-08-14

No numbers diverge beyond the threshold

No divergence does not mean the results are good.

Net profit and operating cash flow
Net profit 8,999억 원, operating cash flow 1조 3,925억 원, 155% of net profit
Sales and receivables
Year on year, sales +28.0%, receivables -25.0%
Receivables 6,158억 원, a year earlier 8,209억 원
Sales and inventory
Year on year, sales +28.0%, inventory -23.8%
Inventory 2조 3,444억 원, a year earlier 3조 772억 원
Profit from outside the core business
Pretax profit 1조 2,252억 원, operating profit 1조 1,672억 원, non-operating result 580억 원
5% of pretax profit came from outside the core business. In the same period last year it was -3%.

Source filing: 2026 first half Report a year earlier

This only checks whether the statement numbers agree with each other. It ignores the share price and is not a reason to buy or sell on its own. See the formula

Company profile

Unqualified opinion

삼성바이오로직스(주)

CEO: 임존종보 (Rim John Chongbo)
Employees: 5,455
Average tenure: 5.3 years
Average pay per employee: ₩114M
Listed: 2016-11-10
Founded: 2011-04-22
Auditor: 삼정회계법인

As filed 2026-10-12

Company site

Sector moves

Of 13 covered Healthcare stocks in Korean, 12 fell; the average change was -3.35%. Samsung Biologics moved in the same direction at -1.48%. Estimated sector flow was outflow.

Variables to watch Drug approvals and trial results, Drug pricing policy, US interest rates, USD/KRW

Risks to check -40% below the high, the downtrend may continue, Clinical trial failure, Drug pricing pressure

Same-sector channels

Latest news

Stock page

Posts are members' opinions. Investment decisions and their consequences are your own.

Data: KRX daily bars, InverseOne quote snapshots, public news feeds, DART filings, InverseOne company research. Not a call to buy or sell.